NCT07024797

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

A Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ABBV-932	Oral Capsule
DRUG	Placebo for ABBV-932	Oral Capsule

Timeline

• Start date: 2025-08-21
• Primary completion: 2025-12-08
• Completion: 2025-12-08
• First posted: 2025-06-17
• Last updated: 2025-12-31

Locations

1 site across 1 country: China